This desk prices things. Monthly cost, what a prepay term locks in, what regain does to the arithmetic of an annual plan — the accounting in the gap between a headline price and a billed one. This paper measures something that appears on no invoice, and it is worth reading for exactly that reason [1].
Two randomized experiments gave participants a short description of a fictional person and varied how that person’s weight history was described. In the first, with 607 participants, the person described as having lost weight on a GLP-1 was rated more negatively than the one who lost it through diet and exercise, and willingness to associate with them differed significantly across conditions.
The second experiment, with 706 participants, tested regain. Here the GLP-1 and diet-and-exercise descriptions were rated similarly, and both were rated worse than the description of someone who had maintained their loss. So the judgment attached to regain is not specific to the drug — it attaches to the regain, whatever produced it. This desk has priced that regain in what six-month discontinuation does to a prepay.
What this study cannot tell you matters as much as what it can. Participants rated a paragraph, not a colleague. Vignette experiments measure stated attitudes toward a described scenario, which is a real thing to measure and is not the same as how anyone behaves toward a person they know. The authors frame their conclusion as a case for stigma-reduction work, not as a measurement of lived treatment.
For a buyer weighing a decision, the practical use is narrow and real. If you have been weighing whether to tell people, this is evidence that the concern is not imagined, and evidence that stopping and regaining carries its own separate judgment — one that lands on everyone who regains, not only on people who used a drug. The financial half of that same decision is in what regain costs after surgery, and the plan-term half is in why annual plans and falling prices do not mix.